No abstract

No abstract

The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care.This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues.First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised.In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics.Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several

Having developed a pharmacokinetic method for studying the fate of orally administered arsenious anhydride by a radioactive tracer method, the influence of Hahnemannian dilutions of arsenicum album on the elimination and retention of this toxin in the rat was then investigated. The effects of centesimal (cH) and decimal (dH) dilutions were studied. All the dilutions studied were found to be active. The strongest effects were observed after the administration of dilutions corresponding to a concentration of 10-14 (14dH and 7cH). Overall, the decimal dilutions augmented the elimination of arsenic more than the centesimals. The observed results were submitted to mathematical analysis. A mathematical model, which confirms that Hahnemannian dilutions have biological effects which are a direct function of the degree of dilution, was developed.